# Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)

> **NCT00759876** · PHASE2 · TERMINATED · sponsor: **PTC Therapeutics** · enrollment: 36 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Ataluren

## Key facts

- **NCT ID:** NCT00759876
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08-13
- **Primary completion:** 2010-05-17
- **Final completion:** 2010-05-17
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Terminated early because similar study with Ataluren (PTC124-GD-007-DMD; NCT00592553) exhibited lack of efficacy at the high dose (not due to safety concerns).
- **Last updated:** 2020-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00759876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00759876, "Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00759876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*